P
Piramal Pharma Ltd
NSE:PPLPHARMA
Piramal Pharma Ltd
NSE:PPLPHARMA
Price:
204.87
INR
-1.79%
Market Closed
Market Cap:
270.7B
INR
Income Statement
Earnings Waterfall
Piramal Pharma Ltd
Piramal Pharma Ltd
|
Revenue
|
91.5B
INR
|
|
Cost of Revenue
|
-32.3B
INR
|
|
Gross Profit
|
59.2B
INR
|
|
Operating Expenses
|
-52.9B
INR
|
|
Operating Income
|
6.3B
INR
|
|
Other Expenses
|
-5.4B
INR
|
|
Net Income
|
911.3m
INR
|
Income Statement
Piramal Pharma Ltd
Piramal Pharma Ltd
Currency: INR
Millions
TTM
| Mar-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||
| Revenue |
70 816
N/A
|
41 222
-42%
|
81 712
+98%
|
64 621
-21%
|
87 038
+35%
|
89 495
+3%
|
91 512
+2%
|
|
| Gross Profit | ||||||||
| Cost of Revenue |
(29 111)
|
(15 149)
|
(31 956)
|
(23 639)
|
(31 604)
|
(32 911)
|
(32 317)
|
|
| Gross Profit |
41 704
N/A
|
26 073
-37%
|
49 756
+91%
|
40 982
-18%
|
55 434
+35%
|
56 584
+2%
|
59 195
+5%
|
|
| Operating Income | ||||||||
| Operating Expenses |
(30 196)
|
(12 820)
|
(34 250)
|
(26 640)
|
(38 971)
|
(45 365)
|
(52 910)
|
|
| Selling, General & Administrative |
(24 163)
|
(9 973)
|
(26 347)
|
(16 295)
|
(21 891)
|
(22 215)
|
(23 075)
|
|
| Research & Development |
(864)
|
0
|
(1 007)
|
0
|
0
|
0
|
0
|
|
| Depreciation & Amortization |
(6 767)
|
(3 707)
|
(7 406)
|
(5 670)
|
(7 592)
|
(7 697)
|
(8 163)
|
|
| Other Operating Expenses |
1 598
|
860
|
509
|
(4 675)
|
(9 488)
|
(15 453)
|
(21 672)
|
|
| Operating Income |
11 509
N/A
|
13 253
+15%
|
15 506
+17%
|
14 342
-8%
|
16 463
+15%
|
11 219
-32%
|
6 285
-44%
|
|
| Pre-Tax Income | ||||||||
| Interest Income Expense |
585
|
(1 884)
|
1 053
|
(2 787)
|
(3 691)
|
(3 634)
|
(3 487)
|
|
| Non-Reccuring Items |
(70)
|
(323)
|
(628)
|
0
|
(628)
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
(5)
|
0
|
(5)
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
(13 221)
|
(9 903)
|
(14 134)
|
(9 537)
|
(8 926)
|
(3 892)
|
1 348
|
|
| Pre-Tax Income |
(1 202)
N/A
|
1 143
N/A
|
1 793
+57%
|
2 018
+13%
|
3 219
+60%
|
3 693
+15%
|
4 146
+12%
|
|
| Net Income | ||||||||
| Tax Provision |
(663)
|
(540)
|
(1 615)
|
(1 790)
|
(2 766)
|
(3 304)
|
(3 235)
|
|
| Income from Continuing Operations |
(1 865)
|
602
|
178
|
227
|
453
|
389
|
911
|
|
| Net Income (Common) |
(1 865)
N/A
|
602
N/A
|
178
-70%
|
227
+28%
|
453
+99%
|
389
-14%
|
911
+134%
|
|
| EPS (Diluted) |
-1.53
N/A
|
0.47
N/A
|
0.14
-70%
|
0.17
+21%
|
0.34
+100%
|
0.31
-9%
|
0.68
+119%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
